The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Real-world data show semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are linked with lower risk of major ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

Please provide your email address to receive an email when new articles are posted on . In SURMOUNT-1, adults with prediabetes receiving tirzepatide were 94% less likely to develop type 2 diabetes ...

A breakthrough obesity and diabetes medication that has reshaped treatment standards abroad has now reached Philippine ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. NEW ORLEANS — Nearly all participants with obesity ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest ...

Tirzepatide starts working quickly. You might notice less hunger in a few days or weeks. Average weight loss in 3 weeks is ...

On Friday, Eli Lilly (NYSE:LLY) won approval of Mounjaro (tirzepatide), a novel once-weekly injectable medicine for type 2 diabetes. Tirzepatide is the first therapy that activates glucagon-like ...

HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...

USA: A large retrospective cohort study found that the dual GIP/GLP-1 receptor agonist tirzepatide was associated with a ...